Orexin regulates bone remodeling via a dominant positive central action and a subordinate negative peripheral action

Cell Metabolism

Volumn 19, Issue 6, 2014, Pages 927-940

  Wei, Wei ^a   Motoike, Toshiyuki ^a,b,c   Krzeszinski, Jing Y ^a   Jin, Zixue ^a   Xie, Xian Jin ^b   Dechow, Paul C ^d   Yanagisawa, Masashi ^a,b,c   Wan, Yihong ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d BAYLOR COLLEGE OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GHRELIN; LEPTIN; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; CD200R1 PROTEIN, MOUSE; NEUROPEPTIDE; OREXIN RECEPTOR; SIGNAL PEPTIDE; SMALL INTERFERING RNA;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE REMODELING; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HOMEOSTASIS; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL; REGULATORY MECHANISM; TRANSGENIC MOUSE; AGONISTS; ANIMAL; BIOSYNTHESIS; BLOOD; BONE DENSITY; BONE DEVELOPMENT; C57BL MOUSE; CELL CULTURE; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; RNA INTERFERENCE;

ANIMALS; BONE DENSITY; BONE REMODELING; CELL DIFFERENTIATION; CELLS, CULTURED; GHRELIN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEPTIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; NEUROPEPTIDES; OREXIN RECEPTORS; OREXINS; OSTEOGENESIS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84902246937     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2014.03.016     Document Type: Article

References (57)

1. H. Aissaoui, R. Koberstein, C. Zumbrunn, J. Gatfield, C. Brisbare-Roch, F. Jenck, A. Treiber, and C. Boss N-Glycine-sulfonamides as potent dual orexin 1/orexin 2 receptor antagonists Bioorg. Med. Chem. Lett. 18 2008 5729 5733
2. J.S. Allard, Y. Tizabi, J.P. Shaffery, C.O. Trouth, and K. Manaye Stereological analysis of the hypothalamic hypocretin/orexin neurons in an animal model of depression Neuropeptides 38 2004 311 315
3. S. Asahi, S. Egashira, M. Matsuda, H. Iwaasa, A. Kanatani, M. Ohkubo, M. Ihara, and H. Morishima Development of an orexin-2 receptor selective agonist, [Ala(11), D-Leu(15)]orexin-B Bioorg. Med. Chem. Lett. 13 2003 111 113
4. I.A. Bab, and R. Yirmiya Depression and bone mass Ann. N Y Acad. Sci. 1192 2010 170 175
5. P.A. Baldock, A. Sainsbury, M. Couzens, R.F. Enriquez, G.P. Thomas, E.M. Gardiner, and H. Herzog Hypothalamic Y2 receptors regulate bone formation J. Clin. Invest. 109 2002 915 921
6. P. Bianco, X. Cao, P.S. Frenette, J.J. Mao, P.G. Robey, P.J. Simmons, and C.Y. Wang The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine Nat. Med. 19 2013 35 42
7. J.P. Bilezikian, R.G. Josse, R. Eastell, E.M. Lewiecki, C.G. Miller, M. Wooddell, A.R. Northcutt, B.G. Kravitz, G. Paul, and A.R. Cobitz et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus J. Clin. Endocrinol. Metab. 98 2013 1519 1528
8. A.M. Blouin, I. Fried, C.L. Wilson, R.J. Staba, E.J. Behnke, H.A. Lam, N.T. Maidment, K.A.E. Karlsson, J.L. Lapierre, and J.M. Siegel Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction Nat. Commun. 4 2013 1547
9. S.L. Borgland, S.J. Chang, M.S. Bowers, J.L. Thompson, N. Vittoz, S.B. Floresco, J. Chou, B.T. Chen, and A. Bonci Orexin A/hypocretin-1 selectively promotes motivation for positive reinforcers J. Neurosci. 29 2009 11215 11225
10. C. Brisbare-Roch, J. Dingemanse, R. Koberstein, P. Hoever, H. Aissaoui, S. Flores, C. Mueller, O. Nayler, J. van Gerven, and S.L. de Haas et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans Nat. Med. 13 2007 150 155
11. L. Brundin, M. Björkqvist, A. Petersén, and L. Träskman-Bendz Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder Eur. Neuropsychopharmacol. 17 2007 573 579
12. R.M. Chemelli, J.T. Willie, C.M. Sinton, J.K. Elmquist, T. Scammell, C. Lee, J.A. Richardson, S.C. Williams, Y. Xiong, and Y. Kisanuki et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation Cell 98 1999 437 451
13. C.D. Cox, M.J. Breslin, D.B. Whitman, J.D. Schreier, G.B. McGaughey, M.J. Bogusky, A.J. Roecker, S.P. Mercer, R.A. Bednar, and W. Lemaire et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3- benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl) phenyl]methanone (MK-4305) for the treatment of insomnia J. Med. Chem. 53 2010 5320 5332
14. P.J. Delhanty, B.C. van der Eerden, M. van der Velde, C. Gauna, H.A. Pols, H. Jahr, H. Chiba, A.J. van der Lely, and J.P. van Leeuwen Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a J. Endocrinol. 188 2006 37 47
15. P. Ducy, M. Amling, S. Takeda, M. Priemel, A.F. Schilling, F.T. Beil, J. Shen, C. Vinson, J.M. Rueger, and G. Karsenty Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass Cell 100 2000 197 207
16. F. Elefteriou, S. Takeda, K. Ebihara, J. Magre, N. Patano, C.A. Kim, Y. Ogawa, X. Liu, S.M. Ware, and W.J. Craigen et al. Serum leptin level is a regulator of bone mass Proc. Natl. Acad. Sci. USA 101 2004 3258 3263
17. N. Fukushima, R. Hanada, H. Teranishi, Y. Fukue, T. Tachibana, H. Ishikawa, S. Takeda, Y. Takeuchi, S. Fukumoto, and K. Kangawa et al. Ghrelin directly regulates bone formation J. Bone Miner. Res. 20 2005 790 798
18. H. Funato, A.L. Tsai, J.T. Willie, Y. Kisanuki, S.C. Williams, T. Sakurai, and M. Yanagisawa Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity Cell Metab. 9 2009 64 76
19. A. Grey Thiazolidinedione-induced skeletal fragility - mechanisms and implications Diabetes Obes. Metab. 11 2009 275 284
20. J. Hara, C.T. Beuckmann, T. Nambu, J.T. Willie, R.M. Chemelli, C.M. Sinton, F. Sugiyama, K. Yagami, K. Goto, M. Yanagisawa, and T. Sakurai Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity Neuron 30 2001 345 354
21. P.D. Home, S.J. Pocock, H. Beck-Nielsen, P.S. Curtis, R. Gomis, M. Hanefeld, N.P. Jones, M. Komajda, J.J. McMurray RECORD Study Team Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 2009 2125 2135
22. S.E. Kahn, S.M. Haffner, M.A. Heise, W.H. Herman, R.R. Holman, N.P. Jones, B.G. Kravitz, J.M. Lachin, M.C. O'Neill, B. Zinman, G. Viberti ADOPT Study Group Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N. Engl. J. Med. 355 2006 2427 2443
23. S.E. Kahn, B. Zinman, J.M. Lachin, S.M. Haffner, W.H. Herman, R.R. Holman, B.G. Kravitz, D. Yu, M.A. Heise, R.P. Aftring, G. Viberti Diabetes Outcome Progression Trial (ADOPT) Study Group Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT) Diabetes Care 31 2008 845 851
24. S.W. Kim, S.J. Her, S.J. Park, D. Kim, K.S. Park, H.K. Lee, B.H. Han, M.S. Kim, C.S. Shin, and S.Y. Kim Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells Bone 37 2005 359 369
25. C. Kotz, J. Nixon, T. Butterick, C. Perez-Leighton, J. Teske, and C. Billington Brain orexin promotes obesity resistance Ann. N Y Acad. Sci. 1264 2012 72 86
26. C.J. Langmead, J.C. Jerman, S.J. Brough, C. Scott, R.A. Porter, and H.J. Herdon Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor Br. J. Pharmacol. 141 2004 340 346
27. N.J. Lee, and H. Herzog NPY regulation of bone remodelling Neuropeptides 43 2009 457 463
28. L. Lin, J. Faraco, R. Li, H. Kadotani, W. Rogers, X. Lin, X. Qiu, P.J. de Jong, S. Nishino, and E. Mignot The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene Cell 98 1999 365 376
29. G. Maccarinelli, V. Sibilia, A. Torsello, F. Raimondo, M. Pitto, A. Giustina, C. Netti, and D. Cocchi Ghrelin regulates proliferation and differentiation of osteoblastic cells J. Endocrinol. 184 2005 249 256
30. R. McGregor, M.F. Wu, G. Barber, L. Ramanathan, and J.M. Siegel Highly specific role of hypocretin (orexin) neurons: differential activation as a function of diurnal phase, operant reinforcement versus operant avoidance and light level J. Neurosci. 31 2011 15455 15467
31. M. Mieda, and T. Sakurai Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status CNS Drugs 27 2013 83 90
32. M. Mieda, J.T. Willie, J. Hara, C.M. Sinton, T. Sakurai, and M. Yanagisawa Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice Proc. Natl. Acad. Sci. USA 101 2004 4649 4654
33. M. Mieda, E. Hasegawa, Y.Y. Kisanuki, C.M. Sinton, M. Yanagisawa, and T. Sakurai Differential roles of orexin receptor-1 and 2 in the regulation of non-REM and REM sleep J. Neurosci. 31 2011 6518 6526
34. S. Nishino, B. Ripley, S. Overeem, G.J. Lammers, and E. Mignot Hypocretin (orexin) deficiency in human narcolepsy Lancet 355 2000 39 40
35. D.V. Novack, and S.L. Teitelbaum The osteoclast: friend or foe? Annu. Rev. Pathol. 3 2008 457 484
36. C. Peyron, J. Faraco, W. Rogers, B. Ripley, S. Overeem, Y. Charnay, S. Nevsimalova, M. Aldrich, D. Reynolds, and R. Albin et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains Nat. Med. 6 2000 991 997
37. S. Rahman, Y. Lu, P.J. Czernik, C.J. Rosen, S. Enerback, and B. Lecka-Czernik Inducible brown adipose tissue, or beige fat, is anabolic for the skeleton Endocrinology 154 2013 2687 2701
38. C.J. Rosen Bone remodeling, energy metabolism, and the molecular clock Cell Metab. 7 2008 7 10
39. T. Sakurai The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness Nat. Rev. Neurosci. 8 2007 171 181
40. T. Sakurai, and M. Mieda Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal Trends Pharmacol. Sci. 32 2011 451 462
41. M.M. Scott, J.N. Marcus, A. Pettersen, S.G. Birnbaum, T. Mochizuki, T.E. Scammell, E.J. Nestler, J.K. Elmquist, and M. Lutter Hcrtr1 and 2 signaling differentially regulates depression-like behaviors Behav. Brain Res. 222 2011 289 294
42. D. Sellayah, P. Bharaj, and D. Sikder Orexin is required for brown adipose tissue development, differentiation, and function Cell Metab. 14 2011 478 490
43. K.L. Stone, S.K. Ewing, L.Y. Lui, K.E. Ensrud, S. Ancoli-Israel, D.C. Bauer, J.A. Cauley, T.A. Hillier, and S.R. Cummings Self-reported sleep and nap habits and risk of falls and fractures in older women: the study of osteoporotic fractures J. Am. Geriatr. Soc. 54 2006 1177 1183
44. Y. Sun, S. Ahmed, and R.G. Smith Deletion of ghrelin impairs neither growth nor appetite Mol. Cell. Biol. 23 2003 7973 7981
45. Y. Wan Bone marrow mesenchymal stem cells: fat on and blast off by FGF21 Int. J. Biochem. Cell Biol. 45 2013 546 549
46. Y. Wan, L.W. Chong, and R.M. Evans PPAR-gamma regulates osteoclastogenesis in mice Nat. Med. 13 2007 1496 1503
47. W. Wei, X. Wang, M. Yang, L.C. Smith, P.C. Dechow, J. Sonoda, R.M. Evans, and Y. Wan PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss Cell Metab. 11 2010 503 516
48. W. Wei, D. Zeve, J.M. Suh, X. Wang, Y. Du, J.E. Zerwekh, P.C. Dechow, J.M. Graff, and Y. Wan Biphasic and dosage-dependent regulation of osteoclastogenesis by β-catenin Mol. Cell. Biol. 31 2011 4706 4719
49. W. Wei, D. Zeve, X. Wang, Y. Du, W. Tang, P.C. Dechow, J.M. Graff, and Y. Wan Osteoclast progenitors reside in the peroxisome proliferator-activated receptor γ-expressing bone marrow cell population Mol. Cell. Biol. 31 2011 4692 4705
50. W. Wei, P.A. Dutchak, X. Wang, X. Ding, X. Wang, A.L. Bookout, R. Goetz, M. Mohammadi, R.D. Gerard, and P.C. Dechow et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ Proc. Natl. Acad. Sci. USA 109 2012 3143 3148
51. J.T. Willie, R.M. Chemelli, C.M. Sinton, S. Tokita, S.C. Williams, Y.Y. Kisanuki, J.N. Marcus, C. Lee, J.K. Elmquist, and K.A. Kohlmeier et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes Neuron 38 2003 715 730
52. C. Willyard New class of sleep drugs may offer a safer night's rest Nat. Med. 18 2012 996
53. I.P. Wong, A.D. Nguyen, E.C. Khor, R.F. Enriquez, J.A. Eisman, A. Sainsbury, H. Herzog, and P.A. Baldock Neuropeptide Y is a critical modulator of leptin's regulation of cortical bone J. Bone Miner. Res. 28 2013 886 898
54. R. Yirmiya, I. Goshen, A. Bajayo, T. Kreisel, S. Feldman, J. Tam, V. Trembovler, V. Csernus, E. Shohami, and I. Bab Depression induces bone loss through stimulation of the sympathetic nervous system Proc. Natl. Acad. Sci. USA 103 2006 16876 16881
55. Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, and J.M. Friedman Positional cloning of the mouse obese gene and its human homologue Nature 372 1994 425 432
56. B. Zinman, S.M. Haffner, W.H. Herman, R.R. Holman, J.M. Lachin, B.G. Kravitz, G. Paul, N.P. Jones, R.P. Aftring, G. Viberti, S.E. Kahn ADOPT Study Group Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes J. Clin. Endocrinol. Metab. 95 2010 134 142
57. A. Ziolkowska, M. Rucinski, M. Tyczewska, and L.K. Malendowicz Orexin B inhibits proliferation and stimulates specialized function of cultured rat calvarial osteoblast-like cells Int. J. Mol. Med. 22 2008 749 755